On January 3, 2025, Haisco Pharmaceutical Group Co., Ltd. announced that Wang Junmin, one of the controlling shareholders and actual controllers of the Company, submitted a letter regarding the addition of a temporary proposal for the "Proposal on the Overall Completion of Fundraising Investment Projects and Subsequent Arrangements for Surplus Funds." The Company stated that this proposal has been reviewed and approved by the 21st meeting of the 5th Board of Directors and is subject to the review of the general meeting of shareholders.